25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Concord Biotech Limited
Buy, Hold or Sell?

Let's analyze Concord Biotech Limited together

I guess you are interested in Concord Biotech Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Concord Biotech Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Concord Biotech Limited

I send you an email if I find something interesting about Concord Biotech Limited.

1. Quick Overview

1.1. Quick analysis of Concord Biotech Limited (30 sec.)










1.2. What can you expect buying and holding a share of Concord Biotech Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.33
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR145.93
Expected worth in 1 year
INR236.41
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR117.80
Return On Investment
5.7%

For what price can you sell your share?

Current Price per Share
INR2,072.70
Expected price per share
INR1,762 - INR2,664
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Concord Biotech Limited (5 min.)




Live pricePrice per Share (EOD)
INR2,072.70
Intrinsic Value Per Share
INR333.74 - INR400.64
Total Value Per Share
INR479.67 - INR546.57

2.2. Growth of Concord Biotech Limited (5 min.)




Is Concord Biotech Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$181.6m$153.5m$28.1m15.5%

How much money is Concord Biotech Limited making?

Current yearPrevious yearGrowGrow %
Making money$36.6m$28.5m$8m22.1%
Net Profit Margin30.9%28.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Concord Biotech Limited (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Concord Biotech Limited?

Welcome investor! Concord Biotech Limited's management wants to use your money to grow the business. In return you get a share of Concord Biotech Limited.

First you should know what it really means to hold a share of Concord Biotech Limited. And how you can make/lose money.

Speculation

The Price per Share of Concord Biotech Limited is INR2,073. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Concord Biotech Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Concord Biotech Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR145.93. Based on the TTM, the Book Value Change Per Share is INR22.62 per quarter. Based on the YOY, the Book Value Change Per Share is INR17.85 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR6.83 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Concord Biotech Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.350.0%0.350.0%0.270.0%0.260.0%0.260.0%
Usd Book Value Change Per Share0.270.0%0.270.0%0.210.0%0.350.0%0.350.0%
Usd Dividend Per Share0.080.0%0.080.0%0.060.0%0.060.0%0.060.0%
Usd Total Gains Per Share0.350.0%0.350.0%0.270.0%0.410.0%0.410.0%
Usd Price Per Share18.10-18.10-0.00-3.62-3.62-
Price to Earnings Ratio51.64-51.64-0.00-10.33-10.33-
Price-to-Total Gains Ratio51.64-51.64-51.64-51.64-
Price to Book Ratio10.42-10.42-0.00-2.08-2.08-
Price-to-Total Gains Ratio51.64-51.64-51.64-51.64-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share24.66513
Number of shares40
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.080.06
Usd Book Value Change Per Share0.270.35
Usd Total Gains Per Share0.350.41
Gains per Quarter (40 shares)14.0216.46
Gains per Year (40 shares)56.0765.83
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1134346105656
2268610221111122
33912915831167188
45217221441222254
56521527051278320
67825832662333386
79130138272389452
810434543882445518
911738849492500584
10130431550103556650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%5.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Concord Biotech Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--22.62022.6200%17.854+27%29.186-22%29.186-22%
Book Value Per Share--145.928145.9280%123.308+18%108.769+34%108.769+34%
Current Ratio--6.3056.3050%3.793+66%4.063+55%4.063+55%
Debt To Asset Ratio--0.1020.1020%0.148-31%0.149-31%0.149-31%
Debt To Equity Ratio--0.1140.1140%0.174-34%0.185-38%0.185-38%
Dividend Per Share--6.8306.8300%5.120+33%5.387+27%5.387+27%
Eps--29.45129.4510%22.949+28%21.548+37%21.548+37%
Free Cash Flow Per Share--17.18517.1850%9.646+78%5.634+205%5.634+205%
Free Cash Flow To Equity Per Share--7.7017.7010%1.500+413%-0.042+101%-0.042+101%
Gross Profit Margin--0.8930.8930%0.901-1%0.904-1%0.904-1%
Intrinsic Value_10Y_max--400.637--------
Intrinsic Value_10Y_min--333.740--------
Intrinsic Value_1Y_max--17.008--------
Intrinsic Value_1Y_min--16.527--------
Intrinsic Value_3Y_max--68.736--------
Intrinsic Value_3Y_min--64.601--------
Intrinsic Value_5Y_max--141.725--------
Intrinsic Value_5Y_min--128.688--------
Market Cap216837583200.000+27%159100323043.200159100323043.2000%-+100%31820064608.640+400%31820064608.640+400%
Net Profit Margin--0.3090.3090%0.281+10%0.311-1%0.311-1%
Operating Margin--0.4130.4130%0.386+7%0.409+1%0.409+1%
Operating Ratio--0.3920.3920%0.661-41%0.560-30%0.560-30%
Pb Ratio14.204+27%10.42210.4220%-+100%2.084+400%2.084+400%
Pe Ratio70.378+27%51.63951.6390%-+100%10.328+400%10.328+400%
Price Per Share2072.700+27%1520.8001520.8000%-+100%304.160+400%304.160+400%
Price To Free Cash Flow Ratio120.614+27%88.49888.4980%-+100%17.700+400%17.700+400%
Price To Total Gains Ratio70.380+27%51.64051.6400%--51.6400%51.6400%
Quick Ratio--6.3706.3700%3.403+87%4.626+38%4.626+38%
Return On Assets--0.1810.1810%0.159+14%0.170+6%0.170+6%
Return On Equity--0.2020.2020%0.186+8%0.208-3%0.208-3%
Total Gains Per Share--29.45029.4500%22.974+28%34.573-15%34.573-15%
Usd Book Value--181670814.500181670814.5000%153510119.000+18%135409540.700+34%135409540.700+34%
Usd Book Value Change Per Share--0.2690.2690%0.212+27%0.347-22%0.347-22%
Usd Book Value Per Share--1.7371.7370%1.467+18%1.294+34%1.294+34%
Usd Dividend Per Share--0.0810.0810%0.061+33%0.064+27%0.064+27%
Usd Eps--0.3500.3500%0.273+28%0.256+37%0.256+37%
Usd Free Cash Flow--21393653.40021393653.4000%12009123.000+78%7013469.680+205%7013469.680+205%
Usd Free Cash Flow Per Share--0.2040.2040%0.115+78%0.067+205%0.067+205%
Usd Free Cash Flow To Equity Per Share--0.0920.0920%0.018+413%-0.001+101%-0.001+101%
Usd Market Cap2580367240.080+27%1893293844.2141893293844.2140%-+100%378658768.843+400%378658768.843+400%
Usd Price Per Share24.665+27%18.09818.0980%-+100%3.620+400%3.620+400%
Usd Profit--36664280.80036664280.8000%28570198.300+28%26825382.220+37%26825382.220+37%
Usd Revenue--118768818.700118768818.7000%101527015.800+17%87489930.500+36%87489930.500+36%
Usd Total Gains Per Share--0.3500.3500%0.273+28%0.411-15%0.411-15%
 EOD+4 -4MRQTTM+0 -0YOY+30 -55Y+24 -1110Y+24 -11

3.3 Fundamental Score

Let's check the fundamental score of Concord Biotech Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1570.378
Price to Book Ratio (EOD)Between0-114.204
Net Profit Margin (MRQ)Greater than00.309
Operating Margin (MRQ)Greater than00.413
Quick Ratio (MRQ)Greater than16.370
Current Ratio (MRQ)Greater than16.305
Debt to Asset Ratio (MRQ)Less than10.102
Debt to Equity Ratio (MRQ)Less than10.114
Return on Equity (MRQ)Greater than0.150.202
Return on Assets (MRQ)Greater than0.050.181
Total8/10 (80.0%)

3.4 Technical Score

Let's check the technical score of Concord Biotech Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.601
Ma 20Greater thanMa 501,889.383
Ma 50Greater thanMa 1001,965.836
Ma 100Greater thanMa 2001,827.751
OpenGreater thanClose2,070.000
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Concord Biotech Limited

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Fundamental data was last updated by Penke on 2024-11-26 07:00:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is overpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Concord Biotech Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Concord Biotech Limited to the Biotechnology industry mean.
  • A Net Profit Margin of 30.9% means that ₹0.31 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Concord Biotech Limited:

  • The MRQ is 30.9%. The company is making a huge profit. +2
  • The TTM is 30.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ30.9%TTM30.9%0.0%
TTM30.9%YOY28.1%+2.7%
TTM30.9%5Y31.1%-0.2%
5Y31.1%10Y31.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ30.9%-115.9%+146.8%
TTM30.9%-210.8%+241.7%
YOY28.1%-214.5%+242.6%
5Y31.1%-342.2%+373.3%
10Y31.1%-464.5%+495.6%
4.3.1.2. Return on Assets

Shows how efficient Concord Biotech Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Concord Biotech Limited to the Biotechnology industry mean.
  • 18.1% Return on Assets means that Concord Biotech Limited generated ₹0.18 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Concord Biotech Limited:

  • The MRQ is 18.1%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 18.1%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ18.1%TTM18.1%0.0%
TTM18.1%YOY15.9%+2.3%
TTM18.1%5Y17.0%+1.1%
5Y17.0%10Y17.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.1%-11.1%+29.2%
TTM18.1%-11.7%+29.8%
YOY15.9%-11.3%+27.2%
5Y17.0%-12.7%+29.7%
10Y17.0%-14.3%+31.3%
4.3.1.3. Return on Equity

Shows how efficient Concord Biotech Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Concord Biotech Limited to the Biotechnology industry mean.
  • 20.2% Return on Equity means Concord Biotech Limited generated ₹0.20 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Concord Biotech Limited:

  • The MRQ is 20.2%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 20.2%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ20.2%TTM20.2%0.0%
TTM20.2%YOY18.6%+1.6%
TTM20.2%5Y20.8%-0.7%
5Y20.8%10Y20.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.2%-14.2%+34.4%
TTM20.2%-15.8%+36.0%
YOY18.6%-13.9%+32.5%
5Y20.8%-18.5%+39.3%
10Y20.8%-19.5%+40.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Concord Biotech Limited.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Concord Biotech Limited is operating .

  • Measures how much profit Concord Biotech Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Concord Biotech Limited to the Biotechnology industry mean.
  • An Operating Margin of 41.3% means the company generated ₹0.41  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Concord Biotech Limited:

  • The MRQ is 41.3%. The company is operating very efficient. +2
  • The TTM is 41.3%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ41.3%TTM41.3%0.0%
TTM41.3%YOY38.6%+2.7%
TTM41.3%5Y40.9%+0.4%
5Y40.9%10Y40.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ41.3%-258.6%+299.9%
TTM41.3%-318.3%+359.6%
YOY38.6%-224.0%+262.6%
5Y40.9%-386.5%+427.4%
10Y40.9%-497.6%+538.5%
4.3.2.2. Operating Ratio

Measures how efficient Concord Biotech Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.39 means that the operating costs are ₹0.39 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Concord Biotech Limited:

  • The MRQ is 0.392. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.392. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.392TTM0.3920.000
TTM0.392YOY0.661-0.269
TTM0.3925Y0.560-0.168
5Y0.56010Y0.5600.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3922.594-2.202
TTM0.3923.360-2.968
YOY0.6613.299-2.638
5Y0.5604.788-4.228
10Y0.5606.528-5.968
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Concord Biotech Limited.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Concord Biotech Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.30 means the company has ₹6.30 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Concord Biotech Limited:

  • The MRQ is 6.305. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.305. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.305TTM6.3050.000
TTM6.305YOY3.793+2.511
TTM6.3055Y4.063+2.242
5Y4.06310Y4.0630.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3053.658+2.647
TTM6.3053.874+2.431
YOY3.7934.672-0.879
5Y4.0635.960-1.897
10Y4.0636.277-2.214
4.4.3.2. Quick Ratio

Measures if Concord Biotech Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Concord Biotech Limited to the Biotechnology industry mean.
  • A Quick Ratio of 6.37 means the company can pay off ₹6.37 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Concord Biotech Limited:

  • The MRQ is 6.370. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.370. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.370TTM6.3700.000
TTM6.370YOY3.403+2.967
TTM6.3705Y4.626+1.744
5Y4.62610Y4.6260.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3703.104+3.266
TTM6.3703.426+2.944
YOY3.4034.498-1.095
5Y4.6265.933-1.307
10Y4.6266.426-1.800
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Concord Biotech Limited.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Concord Biotech Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Concord Biotech Limited to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Concord Biotech Limited assets are financed with 10.2% credit (debt) and the remaining percentage (100% - 10.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Concord Biotech Limited:

  • The MRQ is 0.102. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.102. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.102TTM0.1020.000
TTM0.102YOY0.148-0.046
TTM0.1025Y0.149-0.047
5Y0.14910Y0.1490.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1020.354-0.252
TTM0.1020.345-0.243
YOY0.1480.311-0.163
5Y0.1490.366-0.217
10Y0.1490.382-0.233
4.5.4.2. Debt to Equity Ratio

Measures if Concord Biotech Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Concord Biotech Limited to the Biotechnology industry mean.
  • A Debt to Equity ratio of 11.4% means that company has ₹0.11 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Concord Biotech Limited:

  • The MRQ is 0.114. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.114. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.114TTM0.1140.000
TTM0.114YOY0.174-0.060
TTM0.1145Y0.185-0.071
5Y0.18510Y0.1850.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1140.398-0.284
TTM0.1140.437-0.323
YOY0.1740.378-0.204
5Y0.1850.452-0.267
10Y0.1850.495-0.310
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Concord Biotech Limited generates.

  • Above 15 is considered overpriced but always compare Concord Biotech Limited to the Biotechnology industry mean.
  • A PE ratio of 51.64 means the investor is paying ₹51.64 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Concord Biotech Limited:

  • The EOD is 70.378. Based on the earnings, the company is expensive. -2
  • The MRQ is 51.639. Based on the earnings, the company is expensive. -2
  • The TTM is 51.639. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD70.378MRQ51.639+18.740
MRQ51.639TTM51.6390.000
TTM51.639YOY-+51.639
TTM51.6395Y10.328+41.311
5Y10.32810Y10.3280.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD70.378-2.160+72.538
MRQ51.639-2.428+54.067
TTM51.639-3.145+54.784
YOY--3.304+3.304
5Y10.328-6.080+16.408
10Y10.328-6.625+16.953
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Concord Biotech Limited:

  • The EOD is 120.614. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 88.498. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 88.498. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD120.614MRQ88.498+32.116
MRQ88.498TTM88.4980.000
TTM88.498YOY-+88.498
TTM88.4985Y17.700+70.798
5Y17.70010Y17.7000.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD120.614-2.980+123.594
MRQ88.498-3.295+91.793
TTM88.498-3.682+92.180
YOY--4.523+4.523
5Y17.700-8.162+25.862
10Y17.700-9.239+26.939
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Concord Biotech Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 10.42 means the investor is paying ₹10.42 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Concord Biotech Limited:

  • The EOD is 14.204. Based on the equity, the company is expensive. -2
  • The MRQ is 10.422. Based on the equity, the company is expensive. -2
  • The TTM is 10.422. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD14.204MRQ10.422+3.782
MRQ10.422TTM10.4220.000
TTM10.422YOY-+10.422
TTM10.4225Y2.084+8.337
5Y2.08410Y2.0840.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD14.2041.869+12.335
MRQ10.4222.027+8.395
TTM10.4222.365+8.057
YOY-2.419-2.419
5Y2.0843.668-1.584
10Y2.0844.362-2.278
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-03-312021-03-312022-03-312023-03-312024-03-31
Net Debt  53,430787,960841,390-223,130618,260-337,780280,480-334,525-54,045



6.2. Latest Balance Sheet

Balance Sheet of 2024-03-31. All numbers in thousands.

Summary
Total Assets17,007,085
Total Liabilities1,740,630
Total Stockholder Equity15,266,455
 As reported
Total Liabilities 1,740,630
Total Stockholder Equity+ 15,266,455
Total Assets = 17,007,085

Assets

Total Assets17,007,085
Total Current Assets8,962,311
Long-term Assets8,044,774
Total Current Assets
Cash And Cash Equivalents 151,421
Short-term Investments 2,703,907
Net Receivables 3,496,089
Inventory 2,079,538
Other Current Assets 570,029
Total Current Assets  (as reported)8,962,311
Total Current Assets  (calculated)9,000,984
+/- 38,673
Long-term Assets
Property Plant Equipment 7,864,785
Intangible Assets 3,197
Long-term Assets  (as reported)8,044,774
Long-term Assets  (calculated)7,867,982
+/- 176,792

Liabilities & Shareholders' Equity

Total Current Liabilities1,421,554
Long-term Liabilities319,076
Total Stockholder Equity15,266,455
Total Current Liabilities
Short-term Debt 78,506
Accounts payable 944,353
Other Current Liabilities 307,141
Total Current Liabilities  (as reported)1,421,554
Total Current Liabilities  (calculated)1,330,000
+/- 91,554
Long-term Liabilities
Long-term Liabilities  (as reported)319,076
Long-term Liabilities  (calculated)0
+/- 319,076
Total Stockholder Equity
Common Stock104,616
Retained Earnings 14,049,950
Accumulated Other Comprehensive Income 292,179
Other Stockholders Equity 819,710
Total Stockholder Equity (as reported)15,266,455
Total Stockholder Equity (calculated)15,266,455
+/-0
Other
Cash and Short Term Investments 2,855,328
Common Stock Shares Outstanding 104,616
Current Deferred Revenue36,616
Liabilities and Stockholders Equity 17,007,085
Net Debt -54,045
Net Working Capital 7,540,757
Short Long Term Debt Total 97,376



6.3. Balance Sheets Structured

All numbers in thousands.

 Trend2024-03-312023-03-312022-03-312021-03-312020-03-31
> Total Assets 
9,405,150
11,825,460
13,127,950
15,139,840
17,007,085
17,007,08515,139,84013,127,95011,825,4609,405,150
   > Total Current Assets 
456,200
6,071,470
6,326,660
7,277,020
8,962,311
8,962,3117,277,0206,326,6606,071,470456,200
       Cash And Cash Equivalents 
456,200
51,440
6,670
34,990
151,421
151,42134,9906,67051,440456,200
       Short-term Investments 
1,981,050
1,960,660
1,611,080
1,682,490
2,703,907
2,703,9071,682,4901,611,0801,960,6601,981,050
       Net Receivables 
1,969,234
2,134,130
2,595,240
3,129,186
3,496,089
3,496,0893,129,1862,595,2402,134,1301,969,234
       Other Current Assets 
433,340
748,900
439,851
706,185
570,029
570,029706,185439,851748,900433,340
   > Long-term Assets 
920
5,753,990
6,801,290
7,862,820
8,044,774
8,044,7747,862,8206,801,2905,753,990920
       Property Plant Equipment 
3,809,140
5,577,460
6,435,550
7,654,790
7,864,785
7,864,7857,654,7906,435,5505,577,4603,809,140
       Intangible Assets 
930
64,180
35,790
2,000
3,197
3,1972,00035,79064,180930
       Long-term Assets Other 
-930
2,069,350
1,938,470
1,887,270
2,810,418
2,810,4181,887,2701,938,4702,069,350-930
> Total Liabilities 
1,702,810
1,831,730
2,095,720
2,239,830
1,740,630
1,740,6302,239,8302,095,7201,831,7301,702,810
   > Total Current Liabilities 
1,150,950
1,057,390
1,551,680
1,918,460
1,421,554
1,421,5541,918,4601,551,6801,057,3901,150,950
       Short-term Debt 
135,910
314,000
309,340
251,469
78,506
78,506251,469309,340314,000135,910
       Accounts payable 
712,330
463,970
831,060
938,000
944,353
944,353938,000831,060463,970712,330
       Other Current Liabilities 
302,710
279,420
411,280
638,984
307,141
307,141638,984411,280279,420302,710
   > Long-term Liabilities 
551,860
774,340
544,040
321,370
319,076
319,076321,370544,040774,340551,860
> Total Stockholder Equity
6,485,830
9,993,730
11,032,230
12,900,010
15,266,455
15,266,45512,900,01011,032,2309,993,7306,485,830
   Retained Earnings 
6,485,830
8,777,220
9,815,720
11,683,500
14,049,950
14,049,95011,683,5009,815,7208,777,2206,485,830
   Accumulated Other Comprehensive Income 
0
0
0
0
292,179
292,1790000
   Capital Surplus 00000
   Treasury Stock00000



6.4. Balance Sheets

All numbers in thousands.




6.5. Cash Flows

All numbers in thousands.




6.6. Income Statements

All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-03-31. All numbers in thousands.

Gross Profit (+$)
totalRevenue9,980,573
Cost of Revenue-2,447,837
Gross Profit7,532,7367,532,736
 
Operating Income (+$)
Gross Profit7,532,736
Operating Expense-1,459,703
Operating Income6,261,8526,073,033
 
Operating Expense (+$)
Research Development229,036
Selling General Administrative111,287
Selling And Marketing Expenses331,096
Operating Expense1,459,703671,419
 
Net Interest Income (+$)
Interest Income0
Interest Expense-31,260
Other Finance Cost-31,260
Net Interest Income0
 
Pretax Income (+$)
Operating Income6,261,852
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)4,125,6508,398,054
EBIT - interestExpense = 4,091,937
4,125,650
3,112,292
Interest Expense31,260
Earnings Before Interest and Taxes (EBIT)4,123,1974,156,910
Earnings Before Interest and Taxes (EBITDA)4,659,112
 
After tax Income (+$)
Income Before Tax4,125,650
Tax Provision-0
Net Income From Continuing Ops04,125,650
Net Income3,081,032
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses3,907,540
Total Other Income/Expenses Net-2,136,2020
 

Technical Analysis of Concord Biotech Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Concord Biotech Limited. The general trend of Concord Biotech Limited is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Concord Biotech Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Concord Biotech Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 2,121 < 2,664.

The bearish price targets are: 1,882 > 1,799 > 1,762.

Tweet this
Concord Biotech Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Concord Biotech Limited. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Concord Biotech Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Concord Biotech Limited. The current macd is 34.30.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Concord Biotech Limited price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Concord Biotech Limited. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Concord Biotech Limited price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Concord Biotech Limited Daily Moving Average Convergence/Divergence (MACD) ChartConcord Biotech Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Concord Biotech Limited. The current adx is 24.74.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Concord Biotech Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Concord Biotech Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Concord Biotech Limited. The current sar is 1,877.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Concord Biotech Limited Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Concord Biotech Limited. The current rsi is 69.60. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Concord Biotech Limited Daily Relative Strength Index (RSI) ChartConcord Biotech Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Concord Biotech Limited. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Concord Biotech Limited price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Concord Biotech Limited Daily Stochastic Oscillator ChartConcord Biotech Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Concord Biotech Limited. The current cci is 200.31.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Concord Biotech Limited Daily Commodity Channel Index (CCI) ChartConcord Biotech Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Concord Biotech Limited. The current cmo is 61.13.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Concord Biotech Limited Daily Chande Momentum Oscillator (CMO) ChartConcord Biotech Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Concord Biotech Limited. The current willr is -9.49890332.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Concord Biotech Limited Daily Williams %R ChartConcord Biotech Limited Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Concord Biotech Limited.

Concord Biotech Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Concord Biotech Limited. The current atr is 78.91.

Concord Biotech Limited Daily Average True Range (ATR) ChartConcord Biotech Limited Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Concord Biotech Limited. The current obv is 41,706,451.

Concord Biotech Limited Daily On-Balance Volume (OBV) ChartConcord Biotech Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Concord Biotech Limited. The current mfi is 93.51.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Concord Biotech Limited Daily Money Flow Index (MFI) ChartConcord Biotech Limited Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Concord Biotech Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-11BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-23STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Concord Biotech Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Concord Biotech Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5069.601
Ma 20Greater thanMa 501,889.383
Ma 50Greater thanMa 1001,965.836
Ma 100Greater thanMa 2001,827.751
OpenGreater thanClose2,070.000
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Concord Biotech Limited with someone you think should read this too:
  • Are you bullish or bearish on Concord Biotech Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Concord Biotech Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Concord Biotech Limited

I send you an email if I find something interesting about Concord Biotech Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Concord Biotech Limited.

Receive notifications about Concord Biotech Limited in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.